{'fraction_non_alphanumeric': 0.020309477756286266, 'fraction_numerical': 0.0029013539651837525, 'mean_word_length': 5.46875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prepronociceptin is differentially expressed in epithelial ovarian cancer.

Epithelial ovarian cancer (EOC) is the most lethal gynecologic cancer (1). We sought to identify genes associated with epithelial ovarian cancer and the high-grade serous ovarian cancer (HGSC) subtype by comparing global gene expression profiles of normal ovary with that of primary tumors from women diagnosed with epithelial cancer and HGSC in specific using published microarray data (2, 3). We identified the gene encoding prepronociceptin, PNOC, as among the genes whose expression was most different in epithelial ovarian cancer and in HGSC ovarian tumors. PNOC expression was significantly higher in high-grade serous ovarian tumors relative to normal ovary. PNOC expression correlated with overall survival in patients with ovarian cancer. These data indicate that expression of PNOC is perturbed in epithelial ovarian cancers broadly and in ovarian cancers of the HGSC subtype. PNOC may be relevant to pathways underlying ovarian cancer progression.